Skip to main content
See every side of every news story
Published • loading... • Updated

Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP) - PressReach

Summary by pressreach.com
– Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options – – Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream – WAYNE, Pa., Nov. … Continue reading "Aclaris Therapeutics Initiates Phase 2b Trial of…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pressreach.com broke the news on Monday, November 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal